Last reviewed · How we verify
NCT04979416
Video Messages and Vaccination Intention
NA trial testing Video messages in COVID-19 Vaccination in 1,001 participants. Completed in 22 July 2021.
22 July 2021
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 1,001 |
| Start date | 21 July 2021 |
| Primary completion | 22 July 2021 |
| Estimated completion | 22 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Video messages
Conditions studied
- COVID-19 Vaccination — all drugs for COVID-19 Vaccination →
Sponsor
University of Southern California
Who can join
18 and older, any sex, with COVID-19 Vaccination. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study uses an online panel survey to test the impact of video messages on stated likelihood of COVID-19 vaccination. Participants, who have self-identified as unvaccinated against COVID-19, are randomly assigned to either no video message or 1 of 3 video messages to encourage vaccine take-up. The key endpoint is a question about the likelihood of getting vaccinated in the next 30 days.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interventions to increase COVID-19 vaccine uptake: a scoping review.
Andreas M, Iannizzi C, Bohndorf E, Monsef I, et al · · 2022 · cited 24× · PMID 35920693 · DOI 10.1002/14651858.cd015270
Verify or expand the search:
- PubMed search for NCT04979416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Vaccination
Currently open trials in the same condition.
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
- NCT06613984 — Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) · active not recruiting
- NCT06156254 — Community Care Intervention to Decrease COVID-19 Vaccination Inequities · NA · recruiting
- NCT04967807 — Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) · NA · active not recruiting
- NCT04980560 — Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts · active not recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04979416 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 10 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing